Last reviewed · How we verify
Standard TB treatment
Standard TB treatment uses a combination of antimicrobial agents that inhibit bacterial cell wall synthesis and protein synthesis to kill or suppress Mycobacterium tuberculosis.
Standard TB treatment uses a combination of antimicrobial agents that inhibit bacterial cell wall synthesis and protein synthesis to kill or suppress Mycobacterium tuberculosis. Used for Tuberculosis (drug-susceptible), Latent tuberculosis infection (preventive therapy).
At a glance
| Generic name | Standard TB treatment |
|---|---|
| Also known as | Control arm |
| Sponsor | The Aurum Institute NPC |
| Drug class | Antimycobacterial combination therapy |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
The standard first-line TB regimen typically includes isoniazid (inhibits mycolic acid synthesis in the bacterial cell wall), rifampicin (inhibits bacterial RNA polymerase), pyrazinamide (disrupts bacterial metabolism), and ethambutol (inhibits arabinosyl transferases involved in cell wall synthesis). This multi-drug approach targets multiple pathways simultaneously to prevent resistance and achieve bactericidal activity.
Approved indications
- Tuberculosis (drug-susceptible)
- Latent tuberculosis infection (preventive therapy)
Common side effects
- Hepatotoxicity
- Peripheral neuropathy
- Gastrointestinal disturbance
- Rash
- Hyperuricemia
- Optic neuritis
Key clinical trials
- Parent Study Name: Pulmonary Rehabilitation to Reduce Post-Tuberculosis Morbidity (TB Pure) (NA)
- Prevent TB: Choice Architecture for TPT Delivery (NA)
- Safety and Tolerability of Metformin in People With Tuberculosis (TB) and Human Immunodeficiency Virus (HIV) (PHASE2)
- The DECIDE-TB Trial; Validation of Treatment Decision Algorithms for Childhood Tuberculosis (NA)
- A Nurse Case Management Intervention to Improve MDR-TB/HIV Co-Infection Outcomes (NA)
- Linezolid Tolerance During the BPaL Regimen With Dosage Personalization Based on Therapeutic Drug Monitoring (TDM) During Multidrug-Resistant Tuberculosis Treatment (PHASE4)
- Isoniazid-Related Hepatotoxicity in Clinical Practice: Incidence and Predictors
- AIPH-TB: AI-Optimised Pyrazinamide-Hydroxychloroquine vs Standard RIPE for Drug-Sensitive Pulmonary Tuberculosis - A Phase II RCT (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Standard TB treatment CI brief — competitive landscape report
- Standard TB treatment updates RSS · CI watch RSS
- The Aurum Institute NPC portfolio CI